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Background: Cardiovascular disease (CVD) is the leading cause of death in type 2 diabetes mellitus (T2DM).
American Diabetes Association standards of care set a series of targets recommended for the CVD prevention:
blood pressure, LDL and HDL cholesterol (LDL-C and HDL-C), triglycerides and HbA1c goals. The aim of this study
was to evaluate cardiovascular risk factors in a T2DM outpatient population in order to estimate their specific clinical
value in predicting long-term overall mortality.
Methods: Our study population was composed of 1917 T2DM outpatients attending the hospital-based Diabetes
Clinic of Ferrara for a mean follow-up period of 10 years; recorded information included personal, clinical and
biochemical data, and pharmacological treatment.
Results: A Cox proportional hazard analysis was performed, pointing out as age (HR:1.08; IC95%: 1.06-1.11), sex
(males: HR:1.97; IC95%: 1.26-3.07), mean triglycerides levels during follow-up (III vs I tertile: HR:1.87; IC95%: 1.12-3.12)
and lipid-lowering treatment (HR:0.56; IC95%: 0.35-0.90) were significantly associated with all-cause mortality,
independent of confounding factors such as mean values of LDL-C, HDL-C, HbA1c, blood pressure, BMI, fasting
glucose, and antihypertensive and antidiabetic treatment.
Conclusions: This finding suggests that more attention should be given to the management of cardiovascular
risk in type 2 diabetic patients with high triglycerides levels.Background
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in individuals affected by dia-
betes mellitus; moreover, the rates of CVD mortality
are two to four times higher in diabetic patients compared
with non diabetic population [1]. Usual risk factors for
coronary artery disease (CHD) account for only 25-50%
of increased atherosclerotic risk in diabetes mellitus [2].
Despite achieving targets for low-density lipoprotein
cholesterol (LDL-C), blood pressure and glycemia accord-
ing to current standards of care, patients with dyslipidaemia
remain at high residual risk of vascular events [3]. The
typical pattern of diabetic dyslipidaemia, consisting of
elevated triglycerides, low high-density lipoprotein chol-
esterol (HDL-C), and the predominance of small dense* Correspondence: zlngnn@unife.it
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unless otherwise stated.low-density lipoprotein particles, may contribute to in-
creased CVD mortality in diabetic subjects [4]. Moreover,
in diabetes lipoprotein abnormalities often appears during
the asymptomatic prodromal phase of the disease, while
hyperglycemia is a late stage in the sequence of events
from insulin resistance to frank diabetes.
The clinical conditions commonly associated with type
2 diabetes, such as hypertension and dyslipidaemia, are
critical risk factors for CVD, and diabetes itself confers
an independent risk. Many studies have drown attention
to the efficacy of managing single cardiovascular risk
factors in preventing or delay CVD in diabetic subjects;
[5] for example, LDL-C has been firmly established as a
good predictor of CHD, and statins mega-trials dem-
onstrated that an aggressive LDL-C reduction strategy
effectively reduces cardiovascular complication. Although
this findings, the “residual” risk remains high [6,7].
The 2013 American Diabetes Association (ADA)
standards of care set a series of goals recommended fortd. This is an Open Access article distributed under the terms of the Creative
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1. systolic blood pressure <130 mmHg and diastolic
blood pressure <80 mmHg; 2. LDL-C <100 mg/dL; 3.
triglycerides levels <150 mg/dL; 4. HDL-C >40 mg/dL
in men and >50 mg/dL in women; 5. HbA1c goal of <7%,
with best outcomes obtained when multiple risk factors
are globally addressed [8]. The more recent 2014 stan-
dards of care [9] still call for an aggressive treatment
strategy to reduce LDL-C, blood pressure, and HbA1c
in diabetic patients. Triglycerides levels <150 mg/dL
and HDL-C >40 mg/dL in men and >50 mg/dL in
women remains desirable; however, combination therapy
with drugs adressing trygliceride and HDL-C levels is not
recommeded, since data concerning the management of
high triglycerides levels and low HDL-C levels remains
inconclusive [10,11], and LDL-C–targeted statin therapy
is the preferred strategy. Nonetheless, combination therapy
has been shown not to provide additional cardiovascular
benefit above statin therapy alone, and is not generally
recommended [12].
The aim of the present study was to evaluate a number
cardiovascular risk factors and metabolic parameters in
the type 2 diabetic outpatient population of Ferrara
(Italy) in order to estimate their specific clinical value in
predicting long-term overall mortality.
Methods
We collected data from a sample of 1917 type 2 diabetic
outpatients attending, for the first time, the hospital-based
Diabetes Clinic of Ferrara between 1st January 1996 and
31st December 2006, and subsequently followed until 31st
May 2012.
The recorded information included the following data:
1. Personal, clinical, and lifestyle data including weight,
height, body mass index (BMI), systolic and diastolic
blood pressure, and smoking habit.
2. Clinical history and information relevant to
microvascular (retinopathy, nephropathy and
neuropathy) and macrovascular (CHD,
cerebrovascular disease, and peripheral arterial
disease) complications. Subjects were considered
hypertensive when having mean systolic blood
pressure ≥140 mmHg and/or mean diastolic blood
pressure ≥90 mmHg and/or when they were on
active antihypertensive treatment. Patients were
defined as dyslipidaemic, according to National
Cholesterol Education Program Adult Treatment
Panel III 2004 Guidelines, [13] when having mean
total cholesterol ≥200 mg/dl and/or mean LDL-
C ≥130 mg/dl and/or mean HDL-C <40 mg/dl
for males/<50 mg/dl for females, and/or mean
triglycerides ≥200 mg/dl and/or when on active
lipid-lowering treatment.3. Routine biochemical data including fasting blood
glucose (FBG), glycated haemoglobin (HbA1c), total
cholesterol (TC), triglycerides (TG), HDL-C, LDL-C
(by the Friedewald equation: TC – HDL-C – TG/5),
and creatinine levels at baseline and during follow-up
(minimum, maximum, and mean value). Mean values
were calculated upon all records during follow-up,
with a mean number of 10 visits for each patient
(range: 6 to 15 visits).
4. Pharmacological treatment including
antihypertensive, antidiabetic, and lipid lowering
drugs (statins and/or fenofibrates and/or
omega-3 fatty acids).
All deaths during the period of follow-up were recorded
in two ways: 1. direct contact by telephone with the family
of the patient; 2. direct control of the living status on
provincial death register. However, data about the specific
cause of death were not available for the study.
Statistical analysis
Continuous variables were expressed as mean value ±
standard deviation (SD) or as median value (interquar-
tile range), when appropriate. Categorical variables were
expressed as percentages. Differences between groups
were assessed by the Student’s t test for continuous vari-
ables, the Kruskal-Wallis test for continuous variables
without normal distribution, the x2 test for the categor-
ical data. Multivariate Cox proportional hazard analysis
was used to examine the impact of different metabolic
parameters and treatments on the Hazard Ratio (HR)
for total mortality (method: stepwise backward). The
assumption of proportionality of all variables introduced
in the models was assessed through the analysis of
Schoenfeld residuals. The Cox models were adjusted for
other factors associated with mortality. Two different
models were tested:
– Model 1 included: age and gender; tertiles of BMI;
mean values of fasting blood glucose, HbA1c, systolic
blood pressure, serum LDL-C, HDL-C, and
triglycerides; antihypertensive drugs (yes/no),
lipid-lowering drugs (yes/no), and antidiabetic
treatment. For the latter, five categories were
compared with diet (reference group), including 1.
biguanides, 2. sulfonylureas, 3. biguanides +
sulfonylureas, 4. insulin, and 5. insulin + oral
hypoglycemic agents.
– Model 2 included: age and gender; HbA1c, blood
pressure, LDL-C, HDL-C and triglycerides according
to the ADA goal categories; antihypertensive drugs,
lipid-lowering drugs, and antidiabetic treatment (for
categorization see Model 1). Subjects were categorized
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HDL-C, LDL-C, and triglycerides:1. “satisfying criteria” when mean value and all
recorded values of the variable satisfied the ADA
goal during the whole follow-up (reference group);
2. “partially satisfying criteria” for those individuals
failing to achieve the ADA goal in one or more
situations during follow-up, despite having a mean
value reaching the ADA goal;
3. “not satisfying criteria”: all other subjects.
Analyses were performed by SPSS for Windows statistical
package, version 13.0.
Our research is in compliance with the Helsinki
Declaration. No informed consent was required because




At baseline, the mean age of subjects was 58.0 ± 10.1 SD
years; 40.6% were female. During the 10 years follow-up
period, there were 95 deaths, with a total mortality rate
of 5%. As expected, the deceased group (D) was older and
showed a larger proportion of men (66.3%) compared with
the survivors group (S). The principal characteristic of
the sample at baseline, according to the outcome
(alive/deceased) are summarized in Table 1. Compared
to S group, subjects included in D group had lower sys-





male gender (%) 41.0
e (years) 57.7 ± 10.1
eight (Kg) 83.1 ± 16.5
I (Kg/m2) 29.6 ± 5.2
sting glucose (mg/dl) 144.0 ± 45.6
bA1c (%) 7.4 ± 1.4
stolic blood pressure (mmHg) 136.2 ± 14.5
iastolic blood pressure (mmHg) 79.1 ± 6.9
tal cholesterol (mg/dl) 190.4 ± 40.5
L cholesterol (mg/dl) 108.5 ± 35.6
DL cholesterol (mg/dl) 50.9 ± 14.2
iglycerides (mg/dl)° 139.0 (102.0-190.0
eatinine (mg/dl)°# 0.9 (0.8-1.2)
edian (interquartile range) # Not available in 552 patients.(77 vs 79 mmHg), and higher creatinine levels (1.2 vs
0.9 mg/dl). The principal follow-up characteristic of
the sample, according to the outcome are summarized
in Table 2. Compared to S group, subjects belonging to
D group were characterized by lower mean diastolic
blood pressure (79 vs 80 mmHg), higher mean creatin-
ine levels (1.1 vs 0.9), and higher prevalence of diabetic
dyslipidaemia and microvascular/macrovascular com-
plications, although only nephropathy and retinopathy
were statistically significant (37 vs 17%, and 17 vs 8%,
respectively). Moreover, subjects in D group were more
often treated with insulin (23 vs 7%), and less frequently
treated with lipid lowering drugs and biguanides (26 vs
38%, and 17 vs 33%, respectively), compared with group S.
On the whole, 716 subjects were taking lipid lowering
drugs (62.6%); 640 subjects were taking statins (534 statins
only, 105 statins + omega-3 fatty acids, one statin plus
fibrate), 50 subjects were taking fibrates (46 fibrates only,
three fibrates + omega-3 fatty acids), and 27 subjects were
taking omega-3 fatty acids only.
Cox analysis
In order to evaluate the possible impact of different
variables on long-term total mortality, a Cox propor-
tional hazard analysis was performed by constructing 2
different models (see statistical analysis). In Model 1,
the HR for 10-years total mortality was associated with
male gender (HR: 1.86; 95% CI: 1.20-2.88), age (HR:
1.09; 95% CI: 1.06-1.12), current use of lipid lowering
drugs (HR: 0.56; 95% CI: 0.35-0.90), and serum triglycer-





64.1 ± 9.1 0.001
83.2 ± 19.1 0.94
29.0 ± 5.6 0.34
145.6 ± 57.2 0.74
7.5 ± 1.6 0.61
133.1 ± 15.2 0.04
77.0 ± 6.7 0.004
189.4 ± 40.4 0.81
109.8 ± 34.0 0.72
49.6 ± 15.6 0.39
) 144.0 (105.0-187.0) 0.91
1.2 (0.9-1.8) 0.001





(N = 1822) (N = 95)
Weight (Kg) 83.8 ± 16.4 84.7 ± 17.9 0.57
BMI (Kg/m2) 29.8 ± 5.1 29.5 ± 4.8 0.64
Fasting glucose (mg/dl) 143.3 ± 30.6 148.8 ± 36.9 0.08
HbA1c (%) 7.6 ± 1.2 7.7 ± 1.3 0.22
Systolic blood pressure (mmHg) 136.7 ± 11.9 136.1 ± 12.0 0.66
Diastolic blood pressure (mmHg) 80.4 ± 5.6 79.0 ± 5.2 0.01
Total cholesterol (mg/dl) 196.0 ± 36.1 197.5 ± 37.1 0.71
LDL cholesterol (mg/dl) 113.6 ± 32.2 114.8 ± 31.2 0.72
HDL cholesterol (mg/dl) 50.5 ± 12.8 50.0 ± 13.9 0.74
Triglycerides (mg/dl)° 147.0 (108.0-196.0) 149.5 (115.5-204.0) 0.52
Creatinine (mg/dl)°# 0.9 (0.8-1.1) 1.1 (0.9-1.7) 0.001
Complications (%)
- Hypertension 71.0 74.7 0.25
- Dyslipidaemia 79.5 86.3 0.06
- Coronary hearth disease 5.8 7.4 0.32
- Cerebro-vascular disease 1.3 2.1 0.35
- Peripheral arterial disease 2.9 6.3 0.06
- Nephropathy 17.0 36.8 0.001
- Retinopathy 8.3 16.8 0.007
- Neuropathy 3.0 4.2 0.33
Treatments (%)
Antihypertensive 55.8 63.2 0.09
Lipid-lowering 37.9 26.3 0.01
Antidiabetic
- Only diet 10.0 14.7 0.21
- Biguanides 33.5 16.8 0.001
- Sulfonylureas 4.9 3.2 0.32
- Biguanides + Sulfonylureas 29.6 22.1 0.07
- Insulin 7.0 23.2 0.001
- Insulin + OHA 15.0 20.0 0.12
Mean values were calculated upon all records during follow-up, with a mean number of 10 visits for each patient (range: 6 to 15 visits). The total prevalence of
complications and treatments were evaluated at the time of the end of the study.
°Median (interquartile range) # Not available in 552 patients.
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(HR: 0.47; 95% CI: 0.22-0.96) or biguanides associated
with sulfonylureas (HR: 0.42; 95% CI: 0.21-0.83) was
associated with a reduction in mortality risk compared
to diet treatment.
In Model 2, besides age and gender, the HR for overall
mortality was associated with lipid lowering drugs (HR:
0.56; 95% CI: 0.35-0.91), and triglycerides ADA categories
(HR: Partially satisfying vs Satisfying criteria 2.05; 95% CI:
1.14-3.68; HR: Not satisfying vs Satisfying criteria 1.73;95% CI: 1.08-2.77) (Table 4). Again, the use of biguanides
(HR: 0.45; 95% CI: 0.22-0.96) or biguanides associated
with sulfonylureas (HR: 0.42; 95% CI: 0.21-0.84) was also
associated with a reduction in mortality risk.
Discussion
In this study we evaluated the relative impact of well-
established CVD risk factors in a type 2 diabetic outpatient
population, and estimated their specific value in predicting
long-term all-cause mortality. Indeed, not only patients
Table 3 Hazard Ratios (HR; 95% CI) for 10-years overall mortality in 1917 outpatients with type 2 diabetes mellitus
according to the follow-up parameters (MODEL 1)
Model 1 B SE HR 95% CI p
Inferior Superior
Male gender .62 .22 1.86 1.20 2.88 0.005
Age .08 .01 1.09 1.06 1.12 <0.001
Lipid-lowering drugs -.57 .24 .56 .35 .90 0.017
Triglycerides tertiles
- I tertile 1 - - 0.054
- II tertile .31 .26 1.37 .82 2.30 0.233
- III tertile .63 .26 1.87 1.12 3.13 0.016
Antidiabetic treatment
- Diet 1 - - 0.011
- Biguanides -.76 .37 .47 .22 .96 0.040
- Sulfonylureas -.74 .64 .48 .14 1.67 0.247
- Biguanides + Sulfonylureas -.86 .35 .42 .21 .83 0.013
- Insulin .11 .35 1.11 .56 2.20 0.756
- Insulin + OHA -.21 .37 .81 .39 1.66 0.568
In the Cox model: age, gender; tertiles of Body Mass Index; Fasting Blood Glucose, HbA1c, systolic blood pressure, serum LDL-C, HDL-C, and triglycerides mean
values; antihypertensive drugs, lipid-lowering drugs, and antidiabetic treatment.
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factors compared with non-diabetic individuals, but
many of these are already present in the early stages of
the disease. In particular, diabetic subjects have a pecu-
liar pattern of dyslipidaemia characterized by elevated
triglycerides, low HDL-C, and presence of small-dense
LDLs. This pattern can be often detected before theTable 4 Hazard Ratios (HR; 95% CI) for 10-years overall morta
according to the follow-up parameters (MODEL 2)
Model 2 B SE
Male gender .68 .23
Age .09 .01
Lipid-lowering drugs -.57 .24
Triglycerides ADA categories
- Satisfying criteria
- Partially satisfying criteria .72 .30
- Not satisfying criteria .55 .24
Antidiabetic treatment
- Diet
- Biguanides -.79 .38
- Sulfonylureas -.73 .64
- Biguanides + Sulfonylureas -.86 .35
- Insulin .17 .35
- Insulin + OHA -.18 .37
In the Cox model: age, gender; HbA1c, blood pressure values; serum LDL-C, HDL-C and
drugs, antidiabetic treatment.onset of overt hyperglycaemia, and it is thought to be
secondary to the presence of hyperinsulinemia and
insulin resistance [14] Multiple risk factor interventions
(reducing glucose, lipids, blood pressure, etc.) have been
shown to be effective in reducing all-cause and CVD
mortality in different trials, and should be enforced in
all patients with type 2 diabetes [15]. As a matter of fact,lity in 1917 outpatients with type 2 diabetes mellitus
HR 95% CI p
Inferior Superior
1.97 1.27 3.08 0.003
1.09 1.06 1.12 <0.001
.56 .35 .91 0.019
1 0.025
2.05 1.14 3.68 0.017
1.73 1.08 2.77 0.022
1 0.006
.45 .22 .96 0.038
.48 .14 1.68 0.253
.42 .21 .84 0.014
1.18 .60 2.33 0.630
.84 .41 1.72 0.631
triglycerides categorized by ADA criteria; antihypertensive drugs, lipid-lowering
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sive treatment strategy in order to reduce glucose levels,
blood pressure, and LDL-C in diabetic patients, while
triglycerides levels <150 mg/dL and HDL-C >40 mg/dL
in men and >50 mg/dL in women are only considered
desirable ad not therapeutic goals [16,17]. Our longitu-
dinal data gave us the opportunity to explore the possible
effect of achieving the therapeutic ADA goals and satisfy-
ing desirable triglycerides levels on all-cause mortality.
Serum Triglycerides and 10 years mortality
The contribution of triglycerides to CVD risk has been
much debated in the past, with many important pro-
spective studies observing an association between ele-
vated triglycerides levels and CVD risk (in particular
coronary risk) [18-20], but also risk for microangiopathy
[21]; nevertheless, more recent studies gave different
results, suggesting that this association might be weak-
ened when adjustment for other risk factors was made
[22]. The pathogenetic mechanism undergoing these
findings remains uncertain, and could be mainly related
to triglycerides induced endothelial dysfunction through
oxidative stress. By Cox analysis (Model 1) we demon-
strated a direct association between long-term mortality
risk and triglycerides levels; the association was strong
and significant even after multivariate adjustment for
traditional CVD risk factors including BMI, HbA1c,
LDL-C, and medication use. This independent association
with long term all-cause mortality support the idea that
serum triglycerides could play a role in type 2 diabetic
patients mortality risk [23].
Treating residual risk by lowering triglycerides is still
debated at present time [24]; infact, it is not clear
whether or not a pharmacological intervention targeted
to reducing triglycerides levels would contribute to a
cardiovascular risk reduction [25]. Dedicated trials failed
to find a significant reduction in CVD outcomes in a
diabetic population treated with fenofibrates, [26] while
meta-analyses conducted upon pre-specified subgroups
have confirmed the clinical benefits of fibrates on major
CVD events [27,28]. A randomized clinical trail with
statin therapy plus extended release niacin including over
3,000 patients (one-third with diabetes) with established
cardiovascular disease, low levels of HDL cholesterol, and
triglycerides levels of 150–400 mg/dL, was halted early
due to lack of efficacy on the primary cardiovascular dis-
ease outcome, and a possible increase in ischemic stroke
in those on combination therapy [29]. Hence, combination
lipid-lowering therapy cannot be broadly recommended.
However, ADA guidelines state that triglycerides concen-
trations below 150 mg/dL are desirable. According to this,
in our population, the satisfaction of this “desirable” tri-
glycerides level was associated with a lower 10 years total
mortality. Thereby, we suggest that more attention shouldbe given to cardiovascular risk management in type 2
diabetic patients with high triglycerides levels; specific-
ally, a more strict management of the other modifiable
risk factors (e.g. diet, physical exercise, blood pressure,
LDL-C goal) could be indicated.
As a matter of fact, the second Cox analysis was mod-
elled upon accomplishment of ADA criteria (Model 2),
and confirmed the previous observation; among the cri-
teria established for CVD prevention in patients with
type 2 diabetes, only triglycerides desirable level criteria
(<150 mg/dl) was significantly associated with a lower
mortality risk in our population.
More interesting, diabetic patients belonging to the
“partially satisfying criteria” group (reached triglycerides
target for mean values, but failure in one or more
follow-up visit) had a higher HR for mortality (HR: 2.02;
95% CI: 1.11-3.48) compared to the “satisfying criteria”
reference group (always reached target); besides, their
HR for total mortality was very similar to the “not satisfy-
ing criteria” group (HR: 1.83; 95%IC: 1.08-2.97). We are
not sure about the nature of this finding in the “partially
satisfying criteria” group, and there are at least two pos-
sible explanations: 1. the atherogenic process might be
activated by hypertriglyceridemia, but might successively
continue independently from the persistence of high fast-
ing triglycerides; 2. in this group, unmeasured fluctuations
of triglycerides levels might be present, and might be as
atherogenic and dangerous as high fasting triglycerides
levels, thus predisposing them to a similar increase in the
risk [30].
Lipid-lowering drugs and 10 years mortality
CHD is the most important cause of morbidity and
mortality among subjects with diabetes mellitus. Statins
mega-trial have demonstrated that LDL-C reduction is
effective in reducing cardiovascular mortality in diabetic
subjects; [31] therefore, LDL-C reduction is one of the
primary therapeutic goals in reducing cardiovascular
risk in diabetes [32]. According to these findings, our
data show that the lipid lowering treatment is signifi-
cantly associated with a reduced mortality risk, and this
phenomenon is independent from other variables in-
cluded into the model (HbA1c, blood pressure, LDL-C,
HDL-C, and triglycerides values). The vast majority of
subjects taking lipid lowering drugs were assuming
statins (90%); thus, this class of drugs is most likely to
be responsible of the reduced mortality, independent
from the known effect on serum cholesterol levels. Once
more, there might be evidence of the “very discussed”
pleiotropic effects of statins [33]; these effects may include
reduced endothelial inflammation, nitric oxide production
enhancement, and improved insulin sensitivity [34]. Im-
portant clinical trials such as WOSCOPS [35] and CARE
[36] indicated that, despite comparable serum cholesterol
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events compared with the placebo groups. Most of these
effects might be mediated by the inhibition of isoprenoid
synthesis, which affects multiple signalling pathways.
Biguanides and 10 years mortality
Metformin is considered the first line pharmacological
therapy in type 2 diabetes [37,38]. Its main effect is
enhancement of cell insulin sensitivity [39]. Important
studies, such as the UK Prospective Diabetes Study
(UKPDS), have demonstrated a significant effect of
metformin therapy on overall mortality risk reduction,
and particularly on CVD and myocardial infarction
outcomes [40]. Other clinical and experimental studies
have shown that metformin treatment might be associated
with improved outcomes, supporting the conclusions
from UKPDS. In addition, a well-designed retrospective
analysis has shown significantly lower mortality rates in
patients receiving metformin compared with patients
treated with sulphonylurea monotherapy [41]. The ADA
and EASD consensus guidelines on the management of
hyperglycemia in type 2 diabetes explicitly state that
metformin should be used as first-line therapy, in addition
to lifestyle interventions. Our data are consistent with this
indication, showing that metformin treatment is associ-
ated with a reduced mortality risk compared to diet and
other antidiabetic agents. Nevertheless, we have to make
some considerations upon this result. In particular, patients
treated with metformin had, on average, lower creatinine
levels compared with controls (0.96 ± 0.31 vs 1.12 ± 0.63).
Thus, although this finding is not surprising (metformin
cannot be prescribed in subjects with chronic kidney
disease), the difference in renal function might contribute
to the results.
Finally, we have to acknowledge some important limi-
tations of the study. First, our laboratory data consisted
of only minimum, maximum, and mean values, while
the single laboratory determinations were unavailable.
Second, we disposed of data concerning presence/ab-
sence of micro/macro vascular complications, but we
didn’t have precise additional information upon the
onset of cardiovascular events. Third, we only disposed
of all-cause mortality without any information concerning
the possible cause of death. We would also underline the
strength of our clinical study; indeed, our results are based
on a large sample of older adults type 2 diabetic outpa-
tients (1917 individuals, 40% females) with a long-term
follow-up (on average ten years).
Conclusions
In conclusion, we found a direct association between
mean triglycerides levels and long-term total mortality risk
in older adult type 2 diabetic outpatients; the relationship
was significant even after taking into account for the effectof traditional cardiovascular risk factors and pharmaco-
logical treatments. This finding suggests that more atten-
tion should be given to cardiovascular risk management in
type 2 diabetic patients with high triglycerides levels.
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